A class action lawsuit has been filed against REGENXBIO Inc. alleging that company officials made materially false and misleading statements regarding the efficacy and safety profile of RGX-111, its gene therapy candidate for treating Mucopolysaccharidosis Type I. According to the complaint, defendants lacked a reasonable basis for positive public statements about clinical trial results and overstated the therapeutic potential of the treatment.
The litigation names REGENXBIO as defendant and focuses on statements made during a specified period when the company was actively promoting the gene therapy program. Investors who purchased company securities between February 9, 2022 and January 27, 2026 may qualify as class members in the action. The lawsuit seeks to recover damages allegedly incurred by shareholders as a result of the company's purported misrepresentations.
Interested parties have until April 14, 2026 to file for lead plaintiff status in the case. Investors meeting the eligibility criteria are encouraged to review the complaint filing and understand the procedural requirements for participation.